In this episode, David Flores engages in a conversation with Brett Waters, Esq., the Co-Founder and Executive Director of Reason for Hope, to explore policy and legal reforms aimed at realizing safe, ethical, and affordable access to psychedelic-assisted therapy.
Similar Posts
This Week in Psychedelic Stocks [UPDATES ON MINDMED (MMED/MMEDF) CMPS, NUMI & ATAI, CYBIN]
In today’s episode of “This Week in Psychedelic Stocks”, we’ll see some news on MindMed (MMED / MMEDF/MMQ), Compass Pathways (CMPS), Atai Life Sciences, Numinus Wellness (NUMI), Cybin.
We will cover the latest developments in the field writ large.
This means we will cover any stories that affect the all the companies in this field, as well as company specific developments.
Timestamps:
0:00 – Intro
0:32 – Norway Decriminalization Bill
1:59 – Psychedelic Market Stats
3:21 – Magic Mushrooms to Treat Obesity
5:40 – Ketamine to Treat Suicidal Thoughts?
7:09 -The Acid King?
8:58 – MindMed (MMED/MMEDF/MMQ) Updates
10:04 – Compass Pathways (CMPS) Updates
11:44 – Atai Life Sciences Updates
14:02 – Numinus (NUMI) Updates
15:13 – CYBIN Updates
So this is it for This Week in Psychedelic Stocks fellow psychedelic investors!
I hope you guys found some value in this and I’ll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MindmedStock #PsychedelicStocks
New Psychedelic ETF (PSYK) UPDATE: What Does This Mean For MindMed, NUMI & Compass Pathways?
In our previous video, we discussed the upcoming IPO of Horizons Psychedelic ETF (PSYK).
Recently, on January 27th, PSYK began trading on the Canadian NEO Stock Exchange.
In this episode we are going to discuss the psychedelic ETF and what it means for MindMed, NUMI, Compass Pathways and other stocks in the psychedelic sector.
We will cover a few things such as:
– PSYK’s fundamentals
– PSYK’s CEO Steve Hawkins
-Is Horizons ETF actively or passively managed?
– What psychedelic stocks are included in the ETF?
– How often does th ETF reorganize its stock holdings?
– How is the size of the individual stocks’ position decided on?
– Is it worth investing in PSYK now?
– What will happen to MindMed (MMED/MMEDF), Numinus Wellness (NUMI), Compass Pathways (CMPS) and the other stocks once they are included?
***A quick reminder, the psychedelic sector is at a VERY early stage, and all of these companies, large-cap and small cap alike, will need to attract more funding to complete their clinical trials and bring their products to market. PSYK will however contribute to this sector as it will bring more funding to the industry as a whole, which will both help individual companies and the wider mission of treating mental health disorders.
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#PSYK #MindMed #MMED
Interview with Ian McDonald, CEO & Director of Bright Minds Biosciences
In this wide ranging interview many topics are covered, starting with the philosophy and vision of Bright Minds. We discuss most of Bright Minds’ major projects, including using new psychedelic medicines to treat chronic pain. This is exciting, since it could not only help people with chronic pain issues such as fibromyalgia, but it could also put a dent in the opioid use crisis by preventing people from being prescribed opioids by their doctors to treat pain.
Interview With Joshua White
Fireside Project’s Co-Founder and Director, Joshua White, speaks about the creation and the future of the organization.
Amanita Muscaria and Desert Herbalism with Ash Ritter
We dive into the world of the infamous Amanita Muscaria mushroom and learn about the wild desert apothecary of fungi and herbs.
Introducing the BENZINGA Psychedelic Capital Event | A Psychedelic Investor’s Dream
Buy your tickets to the Benzinga Psychedelics Capital Conference on…